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A B S T R A C T   
Background: Maternal depression and anxiety during pregnancy may enhance fetal exposure to glucocorticoids 
(GCs) and harm neurodevelopment. We tested whether a novel cross-tissue polyepigenetic biomarker indicative 
of in utero exposure to GC is associated with mental and behavioral disorders and their severity in children, 
possibly mediating the associations between maternal prenatal depressive and anxiety symptoms and these child 
outcomes. 
Methods: Children (n = 814) from the Prediction and Prevention of Preeclampsia and Intrauterine Growth Re-
striction (PREDO) study were followed-up from birth to age 7.1–10.7 years. A weighted polyepigenetic GC 
exposure score was calculated based on the methylation profile of 24 CpGs from umbilical cord blood. Child 
diagnosis of mental and behavioral disorder (n = 99) and its severity, defined as the number of days the child had 
received treatment (all 99 had received outpatient treatment and 8 had been additionally in inpatient treatment) 
for mental or behavioral disorder as the primary diagnosis, came from the Care Register for Health Care. Mothers 
(n = 408) reported on child total behavior problems at child’s age of 2.3–5.8 years and their own depressive and 
anxiety symptoms during pregnancy (n = 583). 
Abbreviations: 11β-HSD2, 11-beta-hydroxysteroid-dehydrogenase type 2; ADHD, Attention deficit/hyperactivity disorder; BMI, Body-mass index; CES-D, Center 
for epidemiologic studies depression scale; DNAm, DNA methylation; GC, Glucocorticoid; GR, Glucocorticoid receptor; GRE, Glucocorticoid response element; 
HILMO, Care register for health care; HPA-axis, Hypothalamic-pituitary-adrenal axis; PREDO, Prediction and prevention of preeclampsia and intrauterine growth 
restriction; STAI, Spielberger state anxiety inventory; ZINB, Zero-inflated negative binomial regression. 
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Results: The fetal polyepigenetic GC exposure score at birth was not associated with child hazard of mental and 
behavioral disorder (HR = 0.82, 95% CI 0.54; 1.24, p = 0.35) or total behavior problems (unstandardized beta =
− 0.10, 95% CI -0.31; 0.10, p = 0.33). However, for one standard deviation decrease in the polyepigenetic score, 
the child had spent 2.94 (95%CI 1.59; 5.45, p < 0.001) more days in inpatient or outpatient treatment with any 
mental and behavioral disorder as the primary diagnosis. Criteria for mediation tests were not met. 
Conclusions: These findings suggest that fetal polyepigenetic GC exposure score at birth was not associated with 
any mental or behavioral disorder diagnosis or mother-rated total behavior problems, but it may contribute to 
identifying children at birth who are at risk for more severe mental or behavioral disorders.   
1. Introduction 
Many women experience clinically significant symptoms of depres-
sion and anxiety during pregnancy, with an estimated prevalence of 7%– 
20% (Bennett et al., 2004; Marcus et al., 2003). These maternal mental 
health problems not only complicate the mother’s wellbeing and health 
during pregnancy, but are also associated with increased risk of preterm 
birth, lower birth weight and neurodevelopmental and mental health 
adversities of the offspring later in life (Grote et al., 2010; Madigan et al., 
2018; Robinson et al., 2019; Van den Bergh et al., 2017). The offspring 
neurodevelopmental and mental health adversities include develop-
mental delay (Graignic-Philippe et al., 2014; Tuovinen et al., 2018), 
poorer cognitive functioning (Stein et al., 2014), internalizing and 
externalizing (Kingston et al., 2018; Lahti et al., 2017), attention defi-
cit/hyperactivity (ADHD) (Van Batenburg-Eddes et al., 2013; Wolford 
et al., 2017) and sleep problems (Toffol et al., 2019). In addition, neu-
roimaging studies have shown that maternal depressive and anxiety 
symptoms during pregnancy are associated with alterations in offspring 
structural and functional brain connectivity across various brain regions 
and networks (Adamson et al., 2018; Van den Bergh et al., 2017). 
Mechanisms that could explain these associations remain uncertain. 
It has been postulated that enhanced fetal exposure to glucocorticoids 
(GCs) may be one of the underpinning mechanisms (Reynolds, 2013; 
Wolford et al., 2019; Räikkönen et al., 2020). A number of studies report 
that maternal depression and anxiety during pregnancy are associated 
with higher circulating levels of GC hormone cortisol (Evans et al., 2008; 
O’Connor et al., 2014). This is suggestive of an increased fetal exposure 
to maternal cortisol as the maternal and fetal levels are highly correlated 
(Gitau et al., 1998). However, studies testing associations between 
maternal cortisol levels during pregnancy and offspring neuro-
developmental and mental health outcomes still remain limited 
(O’Donnell and Meaney, 2017). Yet, there is evidence on the effects of 
maternal antenatal administration of exogenous synthetic GCs which are 
transferred through the placenta or increased transfer of cortisol 
through inhibition of the placental GC barrier enzyme 11-beta-hydrox-
ysteroid-dehydrogenase type 2 (11β-HSD2) by, for example, licorice or 
its derivatives (Reynolds, 2013). These exposures are associated with 
poorer learning and memory, anxiety- and depression-like behaviors 
and altered hypothalamic-pituitary-adrenal (HPA)-axis functioning in 
the animal offspring, and poorer cognition, mental health problems and 
altered HPA-axis functioning in the human offspring (Painter et al., 
2012; Räikkönen et al, 2009, 2017, 2020). 
At the molecular level, enhanced fetal glucocorticoid exposure may 
become embedded in fetal epigenetic alterations, such as alterations in 
DNA methylation (DNAm) (Kundakovic and Jaric, 2017; Van Den Bergh, 
2011). In fact, a number of studies have shown that GC exposure can 
lead to changes in DNA methylation, both dynamic and lasting, in part 
mediated by local de-methylation at glucocorticoid receptor (GR) 
binding sites, so called GC response elements (GREs) (Bartlett et al., 
2019; Kress et al., 2006). Studies in animals as well as humans suggest 
that these effects may have cross-tissue impact, with at least some 
overlap of methylation sites responsive to GC in peripheral blood and 
brain tissue (Ewald et al., 2014; Klengel et al., 2013; Wiechmann et al., 
2019). We have recently shown that exposure to GC can lead to lasting 
changes in DNA methylation at CpG sites in a human hippocampal 
progenitor cell line (Provençal et al., 2020), especially when exposure 
happens early in neurodevelopment. These lasting changes in DNA 
methylation are associated with an enhanced transcriptional respon-
siveness of the target genes to a second GC exposure while not changing 
baseline gene expression. This suggests that GC exposure early during 
brain development could leave an epigenetic mark that is associated 
with an altered set point for molecular and cellular responses to future 
stress exposure and thus possibly the individual’s risk or resilience to 
psychiatric disorders (Clayton et al., 2020). We also tested whether a 
biomarker derived from these GC responsive methylation sites showing 
a lasting change in the neuronal cell culture model, would be indicative 
of increased prenatal GC exposure in the newborn (Provençal et al., 
2020). For this, we first identified the overlap of these CpGs with CpG 
sites that showed changes in DNA methylation in peripheral blood cells 
with exposure to the synthetic GC dexamethasone and identified 496 
common CpGs. These cross-tissue GC responsive CpGs were significantly 
enriched among CpGs measured in cord blood that were associated with 
prenatal exposure to synthetic glucocorticoids as well as prenatal 
depression and anxiety. As described above, these latter states have been 
associated with increased maternal cortisol levels. 
Finally, a cross-tissue polyepigenetic score was computed using these 
overlapping 496 CpGs and elastic-net regression, which selected 24 
CpGs within 24 different loci and weighted by GC-induced methylation 
changes in peripheral blood. Measured in fetal cord blood, this score 
correlated inversely with maternal depressive and anxiety symptoms 
during pregnancy. The direction of the association suggested that lower 
scores reflecting more de-methylation after GC, associated with expo-
sure to higher prenatal depression or anxiety symptoms. However, it 
remains unknown if this polyepigenetic GC exposure score at birth 
might allow to identify offspring at risk for neurodevelopmental and 
mental health adversities later in life (Provençal et al., 2020). 
We examined associations between this novel polyepigenetic fetal 
GC exposure score at birth and any mental or behavioral disorder 
diagnosis of the child in a follow-up of from birth to the child’s age of 
7.1–10.7 years. We also examined if the GC exposure score was associ-
ated with the severity of any mental or behavioral disorder diagnosis, 
measured as the number of days the child had spent in inpatient or 
outpatient treatment in public specialized medical care with any mental 
disorder as the primary diagnosis (Wolff et al., 2015), and if the score 
was associated with the mother-rated total behavior problems of the 
child. We further tested if the GC exposure score mediated the associa-
tions between maternal depressive and anxiety symptoms during preg-
nancy and child outcomes. 
2. Methods and materials 
2.1. Participants 
The PREDO study comprises 1079 pregnant women who gave birth 
to a singleton live child in Finland between 2006 and 2010 (Girchenko 
et al., 2017a). Recruitment took place in consecutive order when women 
attended their first ultrasound screening between 12 + 0 and 13 + 6 
gestational weeks + days at one of the ten study hospitals in Southern 
and Eastern Finland. Of the recruited women, 969 had one or more 
clinical risk factors for preeclampsia and/or intrauterine growth 
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restriction (IUGR), and 110 had no known risk factors, including 
maternal pre-pregnancy body mass index (BMI)≥30 kg/m2), pre-
eclampsia or gestational diabetes in previous pregnancy, type 1 dia-
betes, systemic lupus erythematosus, Sjögren’s syndrome, age below 20 
or above 40 years, intrauterine growth restriction or demise of the fetus 
in previous pregnancy (Girchenko et al., 2017a). 
In total, 817 fetal umbilical cord blood samples with full information 
on genome-wide DNAm and genotype were available after quality 
control (see below). 807 umbilical cord blood samples came from the 
1079 pregnancies and 10 from an additional 88 pregnancies from whom 
we sampled placental biopsies (Girchenko et al., 2017a; Lahti-Pulkkinen 
et al., 2018). 
Data on child mental and behavioral disorder diagnoses from birth to 
December 31, 2016 were available for 814 children (99.6%). At the end 
of the follow-up, the children were 7.1–10.7 years of age [Median = 8.4 
(Interquartile range 7.9–9.0)]. Of the 814 children with DNAm, geno-
type and mental and behavioral disorders data, 408 had information on 
mother-rated total behavior problems at the child’s age of 2.3–5.8 years 
[Median = 3.5 (Interquartile range 3.1–4.2)] and 583 had information 
on maternal depressive and anxiety symptoms during pregnancy. See 
Fig. 1 for sample and attrition. 
In comparison to children who were not included in the analytic 
sample (n = 262), those who were included were born at a later gesta-
tional age (Mean Difference (MD) = 0.66 weeks, 95% Confidence In-
terval (95% CI) 0.41; 0.91, p < 0.001), were younger at the end of the 
follow-up (MD = − 0.16 years, 95% CI -0.29; − 0.03, p = 0.005), and 
their mothers had type 1 diabetes less frequently (1.4% vs 4.0%, χ2(1) =
7.29, p = 0.007). The groups did not differ on any other characteristics 
(p > 0.16). 
The Ethics Committees of the Helsinki and Uusimaa Hospital District 
and the participating hospitals approved the study protocol. All 
participating women signed written informed consents. 
2.2. Child DNA methylation and polyepigenetic biomarker of fetal GC 
exposure at birth 
Fetal cord blood samples were collected according to standard pro-
cedures. DNA was extracted at the National Institute for Health and 
Welfare, Helsinki, Finland, and the Institute for Molecular Medicine 
Finland, University of Helsinki, Finland. Methylation analyses were 
performed at the Max Planck Institute of Psychiatry (MPIP) in Munich, 
Germany. DNA was bisulfite converted using the EZ-96 DNA Methyl-
ation kit (Zymo Research, Irvine, CA). Genome-wide methylation status 
of over 485,000 CpG sites was measured using the Infinium Human 
Methylation 450 BeadChip (Illumina Inc., San Diego, CA) according to 
the manufacturer’s protocol. The arrays were scanned using the iScan 
System (Illumina Inc., San Diego, CA). The quality control pipeline was 
set up using the R-package minfi (Aryee et al., 2014). Samples with 
maternal blood contamination were excluded (n = 9) (Morin et al., 
2017). The final dataset contained 428,619 CpG sites. Methylation β 
values were normalized using the funnorm function in the R-package 
minfi (Aryee et al., 2014). 
Weighted polyepigenetic GC exposure score was calculated from the 
selected 24 CpG sites as described previously (Provençal et al., 2020). 
The methylation level of each site was multiplied by the weight and 
summed to get the score for each sample. The weights represent the 
coefficients from the elastic-net regression using dexamethasone asso-
ciated changes in DNA methylation of the CpG sites in peripheral blood 
in the MPIP cohort (Provençal et al., 2020). Appendix A, Figure A1 
shows the distribution of the weighted polyepigenetic GC exposure score 
in the sample (Fig. A1). 
2.3. Child cord blood cell counts at birth 
Cord blood cell composition was estimated for seven cell types 
(nucleated red blood cells, granulocytes, monocytes, natural killer cells, 
Fig. 1. Flow chart of the PREDO study participants and sample attrition.  
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B cells, CD4(+)T cells, and CD8(+)T cells) following the Bakulski et al. 
method (Bakulski et al., 2016) using the R-package minfi (Aryee et al., 
2014). 
2.4. Child genotyping and multidimensional scaling analysis 
Genotyping was performed on Illumina Human Omni Express Exome 
Arrays (Illumina Inc., San Diego, CA). Only markers with a call rate over 
98%, minor allele frequency of 1% and a p-value for deviation from 
Hardy–Weinberg equilibrium > × 10–06 were kept in the analysis. We 
performed multidimensional scaling (MDS) analysis on the identity by 
state matrix of quality-controlled genotypes and identified two MDS 
components depicting the population structure. 
2.5. Child mental and behavioral disorders and total behavior problems 
We identified any mental and behavioral disorder diagnosis in chil-
dren from the Care Register for Health Care (HILMO) between the 
child’s birth in 07.11.2006–24.07.2010 and December 31, 2016. The 
HILMO includes primary and subsidiary diagnoses of all inpatient 
treatments and of outpatient treatments in public specialized medical 
care settings in Finland. We included diagnoses coded F00–F99 ac-
cording to International Statistical Classification of Diseases and Related 
Health Problems, Tenth Revision (ICD-10) in the mental and behavioral 
disorder category. Validation studies have indicated that HILMO has 
high validity for psychiatric diagnoses (Sund, 2012). To study severity of 
any mental and behavioral disorder diagnosis, we summed up the 
number of days the child had been receiving inpatient or outpatient 
treatment for mental or behavioral disorder as the primary diagnosis. 
Total behavior problems were mother-rated using the Child Behavior 
Checklist for ages 1½-5 (Achenbach and Rescorla, 2000). The score 
captures problems in behaviors related to aggression, anxiety, depres-
sion, attention, rule breaking, somatic complains, social problems, 
thought problems and withdrawn behavior. 
2.6. Maternal depressive and anxiety symptoms during pregnancy 
The women completed the questionnaires on depressive and anxiety 
symptoms biweekly up to 14 times throughout pregnancy between 12- 
13 and 38–39 gestational weeks/delivery. Depressive symptoms dur-
ing the past week were measured using the Center for Epidemiologic 
Studies Depression Scale (CES-D) (Radloff, 1977). The 20 CES-D items 
were rated from none (0) to all of the time (3), and a sum score was 
calculated ranging from 0 to 60. 
Anxiety symptoms, reflecting the present state, were measured using 
the Spielberger State Anxiety Inventory (STAI) (Spielberg et al., 1970). 
The 20 STAI items were rated from not at all (1) to very much (4), and a 
sumscore was calculated ranging from 20 to 80. 
We used the 14 time-points raw data to calculate the mean of the 
CES-D and STAI scores to represent the overall depressive and anxiety 
symptoms across pregnancy. 
2.7. Covariates 
All analyses were adjusted for cord blood cell type composition, the 
first two genetic MDS components, child’s sex, child’s birth year, 
gestational age at birth, maternal age at delivery (years), maternal 
smoking during pregnancy (yes/no), maternal education (primary or 
secondary/tertiary), having any of the cardiometabolic conditions dur-
ing pregnancy (hypertensive disorders, gestational diabetes mellitus, 
type 1 diabetes, or pre-pregnancy BMI≥25 kg/m2]), and maternal life-
time diagnosis of any mental disorder. Maternal lifetime diagnosis of 
any mental disorder were derived from HILMO in- and outpatient visits 
(any/no; ICD-9: 290–319, ICD-10: F00–F99 diagnosis codes with inpa-
tient data available between 1987 and 2016 and outpatient data avail-
able between 1998 and 2016). 
In the analysis of the severity of the mental and behavioral disorders 
and total behavior problems, we made additional adjustments for 
follow-up time. 
2.8. Statistical analyses 
With Cox Proportional Hazards models, we estimated the associa-
tions between the GC exposure score and any mental and behavioral 
disorder in children. Before applying the Cox regression analyses, we 
tested if the hazard ratios (HR) changed across time. The time- 
dependent Cox regression analysis detected no time-dependent effects 
(p = 0.87). The proportional hazards assumptions were met, there were 
no outliers, and there was no non-linearity. 
We studied the association between the GC exposure score and 
severity of any mental and behavioral disorder in children using Zero- 
Inflated Negative Binomial (ZINB) regression analysis (Zaninotto and 
Falaschetti, 2011) to account for the excessive number of zeros in the 
outcome count variable. Multiple linear regression tested associations 
between the GC exposure score and total behavior problems in children. 
We pursued to test whether polyepigenetic GC exposure score 
mediated the association between maternal depressive and anxiety 
symptoms during pregnancy and any mental and behavioral disorder, its 
severity and total behavior problems in children using Sobel test. For the 
Sobel test, we derived effect size estimates from Cox Proportional Haz-
ards Model (any mental and behavioral disorder as the outcome), ZINB 
(severity of mental and behavioral disorders as the outcome) and linear 
regression (total behavior problems and polyepigenetic GC exposure 
score as the outcome). Mediation tests were conducted pending that the 
criteria for mediation were met, i.e., that the predictor, mediator and the 
outcome variables were significantly interrelated. 
As effect sizes from Cox models, we present HRs and from linear 
regression unstandardized regression coefficients. From the ZINB 
regression, we report the hurdle negative binomial count model esti-
mates, which reflect the exponential value per unit increase of the 
predictor variable. We further present contrast estimates that reflect the 
inverse number of the exponential values and represent the number of 
days in inpatient or outpatient hospital treatment in our analyses. We 
also present the 95% CIs for all estimates; two-sided p-values < 0.05 
were regarded as significant. 
In Cox models, we stratified the analysis by child’s sex and then 
added all the other covariates into the models. In the ZINB, logit and 
linear regression analysis, we made adjustments for all the covariates. In 
addition, the ZINB model was adjusted for the length of follow-up to the 
child’s last hospital discharge, the logit model was adjusted for child’s 
birth year, and linear model predicting child outcome for child’s age at 
testing. 
Statistical analyses were performed with SAS 9.4 and IBM SPSS 
Statistics 25.0. 
3. Results 
Characteristics of the sample are presented in Table 1. There were 99 
(12.2%) children diagnosed with any mental or behavioral disorder 
during the follow-up. Of them, all 99 children received outpatient 
treatment in public specialized medical care settings and 8 were addi-
tionally hospitalized to inpatient treatment (Table 1). Of the mental and 
behavioral disorder diagnoses, psychological development disorders (n 
= 64, 64.6%) and emotional and behavioral disorders (n = 49, 49.5%) 
were the most common (Table A1). Of the 24 comorbid mental and 
behavioral disorder diagnoses (Table A1), 22 (91.7%) were comorbid 
psychological development and emotional and behavioral disorders. 
Compared with children with no mental disorder, those with any mental 
disorder diagnosis were more often boys and had higher total behavior 
problems scores, their mothers had lower education, higher early 
pregnancy BMI, higher anxiety symptoms during pregnancy, and more 
often a lifetime diagnosis of any mental disorder (p-values<0.05). There 
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were no significant differences in the other characteristics (Table 1). 
Among the 99 children with a diagnosis of any mental and behav-
ioral disorder, the median number of days spent in inpatient or outpa-
tient treatment for any mental and behavioral disorder as the primary 
diagnosis was 7 (Interquartile Range = 2.00–18.00) days. Table A1 
demonstrates that children who had spent 7 days or more in inpatient or 
outpatient treatment had more often a psychological development or 
emotional and behavioral disorder diagnosis and less often a diagnosis 
of behavioral syndromes associated with physiological disturbances and 
physical factors than children who had spent less than 7 days in treat-
ment (p-values <0.035). They also more often had comorbid diagnosis 
in more than one broad category (p < 0.001) (Table A1). 
Of the covariates, child’s sex, gestational age at birth, birth year, 
maternal age at delivery, education, smoking during pregnancy, having 
any cardiometabolic condition and maternal lifetime diagnosis of any 
mental disorder were not significantly associated with the child’s pol-
yepigenetic GC exposure score (p > 0.09) (Table A2). 
3.1. Polyepigenetic GC exposure score and child mental and behavioral 
disorders 
Polyepigenetic GC exposure score was not significantly associated 
with the hazard of being diagnosed with any mental and behavioral 
disorder in children (HR = 0.82, 95% CI 0.54; 1.24, p = 0.35). It was not 
significantly associated with the mother-rated total behavioral problems 
either (unstandardized beta = − 0.10, 95% CI -0.31; 0.10, p = 0.33). 
However, lower polyepigenetic score was significantly associated with 
more days spent in inpatient or outpatient treatment for any mental or 
behavioral disorder as the primary diagnosis (hurdle model estimate =
-1.08 natural logarithm units per each standard deviation (SD) unit in-
crease in polyepigenetic score; 95% CI -1.70; − 0.46, p = 0.001). This 
translated into 2.94 (95% CI 1.59; 5.45, p = 0.001) more days spent in 
in- or outpatient treatment per each SD unit decrease in the poly-
epigenetic score according to contrast estimate results (Fig. 2). A 
Table 1 
Characteristics of the sample.   
Total Sample (N = 814) Сhild Has a Diagnosis of Any 
Mental or Behavioral Disorder (N 
= 99) 
Сhild Has No Diagnosis of Mental or Behavioral 















Sex (Boys) 432 53.1  72 72.7  360 50.3  <0.001 
Age at Follow-Up (until December 31, 2016) (Years) 8.46 0.77 7.06–10.66 8.43 0.77 7.09–10.53 8.46 0.77 7.06–10.66 0.73 
Polyepigenetic GC Exposure Score − 1.13 0.21 − 1.78–− 0.49 − 1.14 0.19 − 1.72–− 0.75 − 1.13 0.21 − 1.78–− 0.49 0.59 
Gestational Age (weeks) 39.77 1.60 31.00–42.71 39.80 1.66 31.57–42.14 39.76 1.59 31.00–42.71 0.84 
Inpatient Treatment for Any Mental or Behavioral 
Disorder (yes) 
8 1.0  8 8.1  NA NA NA NA 
Outpatient Treatment for Any Mental or Behavioral 
Disorder (yes) 
99 100  99 100  NA NA NA NA 
Number of Days the Child Has Been in In- or 
Outpatient Treatment for Any Mental or 
Behavioral Disorder as the Primary Diagnosis 
(days) 
1.77 8.89 0.00–108.00 14.57 21.63 1.00–108.00 NA NA NA NA 
Inpatient 0.07 0.96 0.00–18.00 0.60 2.69 0.00–18.00 NA NA NA NA 
Outpatient 1.70 8.76 0.00–108.00 13.97 21.52 1.00–108.00 NA NA NA NA 
Total Behavior Problems 24.93 15.67 0.00–91.00 33.44 20.16 4.00–91.00 23.87 14.72 0.00–88.00 p <
0.001 
Maternal Characteristics 
Age at Delivery (years) 33.29 5.78 17.17–47.39 32.90 5.83 19.47–44.56 33.34 5.78 17.17–47.39 0.48 
Education          0.002 
Primary/Secondary 358 45.3  59 60.2  299 43.2   
Tertiary 432 54.7  39 39.8  393 56.8   
Smoking during Pregnancy (yes) 34 4.2  5 5.1  29 4.0  0.64 
Hypertension Disorder During Pregnancy (yes) 276 33.9  41 41.4  235 32.8  0.092 
Gestational Diabetes Mellitus (yes) 182 22.4  27 27.6  155 21.7  0.20 
Type 1 Diabetes Mellitus (yes) 11 1.4  3 3.1  8 1.1  0.12 
Pre-Pregnancy BMI (kg/m2) 27.27 6.78 17.30–55.00 28.63 6.46 17.51–49.82 27.24 6.40 17.30–55.00 0.044 
Lifetime Diagnosis of Any Mental Disorder (yes) 130 16.0  27 27.3  103 14.4  0.001 
Antenatal Mean Score of Depressive Symptoms (CES- 
D) 
11.32 6.47 0.50–44.69 12.70 7.62 0.57–44.69 11.13 6.28 0.50–38.64 0.055 
Antenatal Mean Score of State-Trait Anxiety (STAI) 33.91 7.90 20.36–67.76 35.97 8.70 20.43–58.07 33.62 7.75 20.36–67.76 0.019 
P refers to p-values derived from the t-test and Chi-square test when comparing the children with any mental or behavioral disorder diagnosis (N = 99) with the 
children with no diagnosis for mental or behavioral disorder (N = 715). 
For total behavior problems the sample size is n = 408: children with diagnosis, n = 45, children without diagnosis n = 363. 
Abbreviations: GC, glucocorticoid; BMI, body mass index; CES-D, Center for epidemiologic studies depression scale; STAI, Spielberger state anxiety inventory. 
Fig. 2. The number of days the child has spent in any inpatient treatment or in 
outpatient treatment in public specialized medical care with any mental or 
behavioral disorder as the primary diagnosis (N = 99) according to the poly-
epigenetic glucocorticoid exposure score at birth categorized into tertiles. 
Horizontal lines refer to the medians and inter-quartile ranges and cross marks 
to the mean values. 
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scatterplot with a smooth fitted line (loess fit) indicated that the asso-
ciation between the GC exposure score and the number of days the child 
had spent in inpatient or outpatient treatment was not non-linear and 
that there was no indication of a clear threshold effect (Figure A2). 
3.2. Polyepigenetic GC exposure score as a mediator 
Before proceeding to mediation analyses, we tested if the criteria for 
mediation were met. We have previously shown in a subsample of the 
current sample, namely in women who reported depressive and anxiety 
symptoms during pregnancy that higher maternal anxiety and depres-
sive symptoms were associated with a lower polyepigenetic score in the 
offspring (Provençal et al., 2020), and the above analyses showed that 
the score was also associated with a higher number of days spent in 
inpatient or outpatient treatment. However, in the subsample of the 583 
women who reported depressive and anxiety symptoms during preg-
nancy, these symptoms were not significantly associated with the 
number of days the child had spent in the inpatient or outpatient 
treatment (depressive symtpoms: hurdle model estimate = 0.003; 95% 
CI -0.06; 0.07, p = 0.94; anxiety symptoms: hurdle model estimate =
0.02; 95% CI -0.04; 0.07, p = 0.58). Hence, we did not pursue mediation. 
However, in post hoc analyses in the entire PREDO cohort with data 
available on maternal depressive (n = 3404) and anxiety symptoms (n =
3405) during pregnancy, higher maternal depressive and anxiety 
symptoms were associated with 1.31 (95% CI 1.07; 1.61; (hurdle model 
estimate = 0.27, 95% CI 0.06; 0.48, p = 0.011) and 1.32 (95% CI 1.08; 
1.62; hurdle model estimate = 0.28, 95% CI 0.08; 0.48, p = 0.007) more 
days spent in inpatient or outpatient treatment, respectively, per each 
SD unit increase in the symptomatology. This is suggestive of a possible 
mediation effect in a cohort with greater statistical power. 
4. Discussion 
We showed here that a novel polyepigenetic biomarker based on 24 
CpG sites reflecting fetal GC exposure at birth was not significantly 
associated with higher hazard for any childhood mental or behavioral 
disorder or with mother-reported total behavior problems. However, it 
was significantly associated with the severity of any mental or behav-
ioral disorder diagnosis, such that lower polyepigenetic GC exposure 
score at birth was associated with more days spent in inpatient or 
outpatient treatment for any mental and behavioral disorder as the 
primary diagnosis. For each SD unit decrease in this score, the child had 
spent almost three more days in inpatient or outpatient treatment. These 
findings, thus, suggest that this novel polyepigenetic biomarker may 
contribute to identification of children at birth who are at risk for more 
severe mental and behavioral disorders, enabling timely targeted pre-
ventive interventions, before any manifest symptoms or disorders occur. 
In our study sample, we have previously shown that the fetal poly-
epigenetic GC exposure score correlated with maternal depressive and 
anxiety symptoms during pregnancy (Provençal et al., 2020). However, 
in the subsample studied here, maternal depressive and anxiety symp-
toms were not associated with the severity of child mental and behav-
ioral disorders. Hence, our study did not allow us to test for mediation. 
However, in a larger sample of the PREDO study, for whom we missed 
cord blood samples, maternal higher depressive and anxiety symptoms 
were significantly associated with 1.3 more days spent in in- or outpa-
tient treatment, suggesting insufficient power in the current subset to 
detect this association. 
The fact that a lower polyepigenetic GC exposure score was associ-
ated with higher severity of child mental and behavioral disorders is in 
line with an increased prenatal GC exposure in the severely affected 
children. We have previously shown that a lower polyepigenetic GC 
exposure score is reflective of DNA de-methylation with GR activation 
(Provençal et al., 2020). In fact, exposure to GC has been associated with 
DNA de-methylation specifically at glucocorticoid-responsive elements 
(Wiechmann et al., 2019). These findings would suggest that children 
with more severe symptoms have been exposed to more GC prenatally or 
are more sensitive, which is reflected in their epigenetic profiles. This 
may be indicative of an increased priming of target genes to subsequent 
stress exposure, as suggested by our findings in hippocampal progenitor 
cells (Provençal et al., 2020). Furthermore, combining GC exposure of 
human cerebral organoids as a model of early brain development and 
single cell sequencing, we showed that GC target genes in the developing 
brain are enriched for genes that have been associated with neuro-
developmental disorders and psychiatric disease, including major 
depression, schizophrenia as well as cross disorders risk in large 
genome-wide association studies (Cruceanu et al., 2020). The strongest 
disease enrichments were found for transcripts regulated in late 
neuronal progenitors and neurons. This would suggest that prenatal GC 
exposure may contribute to the increased risk for more severe mental 
and behavioral disorders observed in the offspring via lasting epigenetic 
changes in relevant neuronal target genes and that this risk maybe 
exacerbated in with additional genetic risk (O’Donnell and Meaney, 
2017). 
Our study has several strengths. First, our study design was pro-
spective, and our mother–child cohort was well-characterized. This 
allowed us to account for several important covariates in our analyses 
that have been shown to alter cord blood methylation levels, including 
cell-type composition, genetic background, child’s sex, gestational age 
at birth and age at follow-up, maternal age at delivery, smoking during 
pregnancy, level of education, cardiometabolic conditions during 
pregnancy, and maternal lifetime diagnosis of any mental disorder 
(Alfano et al., 2019; Bakulski et al., 2016; Barfield et al., 2014; Girch-
enko et al., 2017b; Rauschert et al., 2019). 
Second, our study utilized data from a validated nationwide 
healthcare registry on child mental and behavioral disorder diagnoses as 
well as on the number of days the child had been in in- or outpatient 
treatment for these disorders as the primary diagnosis (Sund, 2012). 
This is likely to decrease the common-method bias present in studies 
where both the predictor and the outcome are reported by the same 
person (Podsakoff et al., 2003). In addition, since the registry data has 
almost 100% coverage, registry data attrition in our study was nearly 
zero (0.4%), which increases generalizability from our findings. How-
ever, data attrition was almost 50% for mother-reported total behavior 
problems in children, which limits generalizability and statistical power. 
Furthermore, the polyepigenetic score was derived from cross-tissue 
overlap of GC responsive CpG sites of neuronal cell lines and peripheral 
blood. In fact, DNA methylation patterns are largely tissue specific, so a 
cross-tissue score is relevant as a biomarker for deciphering the potential 
long-term impact of stress. In addition, the use of a pharmacological 
stimulus allows better interpretation of the directionality of the 
observed association in a biological context – lower scores are reflective 
of more de-methylation with GC and thus increased prenatal GC expo-
sure or increased epigenetic sensitivity to their effects. 
The main limitation of our study relates to the comparatively low 
number of children with mental and behavioral disorders leading to 
decreased statistical power to study any mental and behavioral disorder 
in children. In proportion (12.1%) this number is, however, slightly 
higher in magnitude than that found in the general population of Finnish 
children (Räikkönen et al., 2020). Moreover, our study was limited to 
disorders carrying higher prevalence in childhood, namely psychologi-
cal development and behavioral and emotional disorders. These disor-
ders were also more prevalent in the children who had spent 7 or more 
days, the median number of, days in in- or outpatient treatment for 
mental and behavioral disorder as the primary diagnosis. As many 
psychiatric disorders manifest in adolescence and later in life (Paus 
et al., 2008) further follow-up of the PREDO cohort as the children age is 
warranted. 
Another limitation is the epidemiological design, restricting causal 
inferences. Furthermore, since the vast majority of our sample came 
from the high-risk sample for preeclampsia and IUGR, population-wide 
studies are needed to confirm if our findings may extend to all pregnant 
A. Suarez et al.                                                                                                                                                                                                                                  
Neurobiology of Stress 13 (2020) 100275
7
women and their children. Furthermore, our sample was ethnically 
homogeneous with the majority of Caucasians, therefore, generaliz-
ability is limited. 
Finally, even though we accounted for a number of important 
covariates, we cannot rule out that some other unmeasured factor might 
explain our findings, and hence cannot rule out residual confounding. 
Other factors operating in the postnatal environment may be driving the 
discovered associations. Such postnatal factors may include diet, 
neurotoxic exposures, use of corticosteroids, and stress, which may in-
fluence child DNAm, and thereby increase the child’s risk for mental and 
behavioral disorders (Barker et al., 2018). It is yet unclear whether the 
initial prenatal insult may induce immediate pathophysiological out-
comes and/or whether the initial exposure may lead to cellular 
reprogramming via DNAm and other biological mechanisms that prime 
differential responses to the same environmental conditions later on that 
then lead to pathology (McGowan and Matthews, 2018). Therefore, 
more longitudinal studies with multiple DNAm measurements and 
evaluation of polyepigenetic GC exposure scores, which account for both 
pre- and postnatal adversities in relation to child neurodevelopment, are 
needed. 
5. Conclusions 
Our findings showed that fetal polyepigenetic GC exposure score at 
birth was not significantly associated with a higher hazard for any 
mental or behavioral disorder or with mother-reported total behavior 
problems, but a lower fetal polyepigenetic GC exposure score at birth 
was associated with more severe mental or behavioral disorder as 
indicated by more days spent in inpatient or outpatient treatment with 
any mental or behavioral disorder as the primary diagnosis. The poly-
epigenetic biomarker of fetal GC exposure holds potential for early 
identification of children at risk for mental and behavioral disorders for 
timely targeted interventions and may also provide opportunities for 
developing therapeutic targets. 
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